non-small cell lung cancer
Conditions
Interventions
single arm:Anlotinib combined with TKI
Sponsors
The Second Affiliated Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18-75 years old, male or female, ECOG PS score : 0-2; 2. Expected survival not less than 12 weeks; 3. A histopathologically or cytologically diagnosed IIIB-IV stage non-small cell lung cancer, with a measurable lesions (according to RECIST 1.1 standard, tumor lesions on CT scan length >= 10 mm); 4. The EGFR gene status was detected by NGS as a sensitive mutation (19 exon deletion or 21 exon L858R site mutation); 5. After the first-line treatment with first-generation TKI, patients with slow disease progression were tested again for negative T790M; 6. No targeted drugs against tumor angiogenesis have been used before; 7. The fuctions of main organs are nomal.
Exclusion criteria
Exclusion criteria: 1. Small cell carcinoma mixed non-small cell carcinoma; 2. Symptomatic brain metastases; 3. Imaging (CT or MRI) showed that the tumor lesion was no more than 5mm away from the great vessels, or there was a central lung cancer invading into the local great vessels; 4. Patients with positive gene test results for T790M mutation; 5. Patients with hemoptysis or hemorrhagic disease, or with a high risk of bleeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate;PFS;Overall survival; | — |
Countries
China
Contacts
Public ContactWeiliang Sun
The Second Affiliated Hospital of Guangxi Medical University
Outcome results
None listed